Short-term effects of secukinumab on bone turnover markers (BTM) and Dkk-1 and sclerostin in Patients with Psoriatic Arthritis
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Biomarker; Pharmacodynamics
- 06 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism